Aclaris Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for ACLARIS, and when can generic versions of ACLARIS drugs launch?
ACLARIS has one approved drug.
There are six US patents protecting ACLARIS drugs.
There are twenty-nine patent family members on ACLARIS drugs in eighteen countries and thirty-five supplementary protection certificates in ten countries.
Drugs and US Patents for Aclaris
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aclaris | ESKATA | hydrogen peroxide | SOLUTION;TOPICAL | 209305-001 | Dec 14, 2017 | DISCN | Yes | No | 10,729,720 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Aclaris | ESKATA | hydrogen peroxide | SOLUTION;TOPICAL | 209305-001 | Dec 14, 2017 | DISCN | Yes | No | 9,980,983 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Aclaris | ESKATA | hydrogen peroxide | SOLUTION;TOPICAL | 209305-001 | Dec 14, 2017 | DISCN | Yes | No | 9,675,639 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Aclaris | ESKATA | hydrogen peroxide | SOLUTION;TOPICAL | 209305-001 | Dec 14, 2017 | DISCN | Yes | No | 7,381,427 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Aclaris
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Aclaris | ESKATA | hydrogen peroxide | SOLUTION;TOPICAL | 209305-001 | Dec 14, 2017 | 7,381,427 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Aclaris Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Israel | 157321 | ⤷ Try a Trial |
Japan | 6622217 | ⤷ Try a Trial |
European Patent Office | 1365781 | ⤷ Try a Trial |
Russian Federation | 2711662 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Aclaris Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
3106463 | 2020C/507 | Belgium | ⤷ Try a Trial | PRODUCT NAME: VITRAKVI - LAROTRECTINIB ET/OU SES SELS ACCEPTABLES EN PHARMACIE, EN PARTICULIER L'HYDROGENO SULFATE DE LAROTRECTINIB; AUTHORISATION NUMBER AND DATE: EU/1/19/1385 20190923 |
2523731 | 122020000026 | Germany | ⤷ Try a Trial | PRODUCT NAME: OSILODROSTAT ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, EINSCHLIESSLICH OSILODROSTATDIHYDROGENPHOSPHAT; REGISTRATION NO/DATE: EU/1/19/1407 20200109 |
0302769 | 98C0036 | Belgium | ⤷ Try a Trial | PRODUCT NAME: CLOPIDOGREL HYDROGENE SULFATE; REGISTRATION NO/DATE IN FRANCE: EU/1/98 /069/001 DU 19980715; REGISTRATION NO/DATE AT EEC: DU EU/1-/98/069/001 |
3106463 | 2020004 | Norway | ⤷ Try a Trial | PRODUCT NAME: LAROTREKTINIB OG/ELLER FARMASOEYTISK AKSEPTABLE SALTER DERAV, SAERLIG LAROTREKTINIBSULFAT INKLUDERT LAROTREKTINIBHYDROGENSULFAT; REG. NO/DATE: EU/1/19/1385 20191018 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.